Actuate Therapeutics, founded with a mission to innovate in the treatment of high-impact cancers and neurodegenerative diseases, is a private biopharmaceutical company. The company focuses on developing compounds aimed at treating cancer, inflammatory diseases leading to fibrosis, and neurodegenerative conditions. Actuate's lead product, elraglusib, is a novel GSK-3 inhibitor designed to slow, stop, or shrink tumors with minimal adverse effects. The company targets patients with hard-to-treat cancers, aiming to improve their quality of life and survival rates.

Notable figures affiliated with Actuate Therapeutics include experts in oncology and neurodegenerative research. The company has attracted significant investment from private equity firms and venture capitalists specializing in biopharmaceutical innovations. Key achievements include advancing elraglusib through various stages of clinical trials, demonstrating its potential efficacy and safety. Actuate Therapeutics has made a substantial impact by offering new hope to patients with limited treatment options, contributing to the broader field of cancer and neurodegenerative disease research.